GlassScriptPhysician profile
Wei-Ann Hsueh
NPI 1255652806
$933.70
in general payments reported to CMS, 2019-2025
14 companies · $484 in 2025
The $484 reported for 2025 was more than what 78% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $18.15 · 2021: $53.03 · 2023: $140 · 2024: $239 · 2025: $484.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $863.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $862.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $267.46 | 2023-2025 | Entyvio |
| Lilly USA, LLC | $158.32 | 2024-2025 | Omvoh |
| Ardelyx, INC. | $93.44 | 2025 | Ibsrela |
| Janssen Biotech, INC. | $84.51 | 2024-2025 | Tremfya, Stelara |
| Abbvie INC. | $78.66 | 2021-2025 | |
| Celltrion USA INC. | $65.46 | 2024-2025 | Vegzelma |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.71 | 2023 | Cyltezo |
| Regeneron Healthcare Solutions, INC. | $27.60 | 2025 | Dupixent |
| Nestle Healthcare Nutrition INC. | $24.74 | 2023 | |
| Aimmune Therapeutics, INC. | $23.99 | 2024 | |
| Merck Sharp & Dohme LLC | $21.90 | 2024 | Dificid |
| Ipsen Biopharmaceuticals, INC | $21.80 | 2025 | Iqirvo |
| Intercept Pharmaceuticals, INC. | $18.15 | 2020 | |
| Genzyme Corporation | $17.96 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wei-Ann Hsueh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.